Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
Clinical outcomes with the MammoSite radiation therapy system: results of a prospective trial.

Journal of radiation oncology

Small W, Refaat T, Strauss JB, Gopalakrishnan M, Bethke KP, Mendelson EB, Wolfman JA, Jovanovic BD, Kiel K.
PMID: 26779307
J Radiat Oncol. 2015 Dec;4(4):395-400. doi: 10.1007/s13566-015-0228-1. Epub 2015 Nov 02.

OBJECTIVE: The purpose of this study was to report the treatment-induced adverse events and cosmetic and treatment outcomes of accelerated partial breast irradiation (APBI) delivered with the MammoSite radiation therapy system (RTS) in breast cancer patients undergoing breast-conserving therapy...

Cite
Small W, Refaat T, Strauss JB, et al. Clinical outcomes with the MammoSite radiation therapy system: results of a prospective trial. J Radiat Oncol. 2015;4(4):395-400doi: 10.1007/s13566-015-0228-1.
Small, W., Refaat, T., Strauss, J. B., Gopalakrishnan, M., Bethke, K. P., Mendelson, E. B., Wolfman, J. A., Jovanovic, B. D., & Kiel, K. (2015). Clinical outcomes with the MammoSite radiation therapy system: results of a prospective trial. Journal of radiation oncology, 4(4), 395-400. https://doi.org/10.1007/s13566-015-0228-1
Small, William, et al. "Clinical outcomes with the MammoSite radiation therapy system: results of a prospective trial." Journal of radiation oncology vol. 4,4 (2015): 395-400. doi: https://doi.org/10.1007/s13566-015-0228-1
Small W, Refaat T, Strauss JB, Gopalakrishnan M, Bethke KP, Mendelson EB, Wolfman JA, Jovanovic BD, Kiel K. Clinical outcomes with the MammoSite radiation therapy system: results of a prospective trial. J Radiat Oncol. 2015 Dec;4(4):395-400. doi: 10.1007/s13566-015-0228-1. Epub 2015 Nov 02. PMID: 26779307; PMCID: PMC4710168.
Copy Download .nbib Format: NLM
Cavernosal nerve functionality evaluation after magnetic resonance imaging-guided transurethral ultrasound treatment of the prostate.

World journal of radiology

Sammet S, Partanen A, Yousuf A, Sammet CL, Ward EV, Wardrip C, Niekrasz M, Antic T, Razmaria A, Farahani K, Sokka S, Karczmar G, Oto A.
PMID: 26753067
World J Radiol. 2015 Dec 28;7(12):521-30. doi: 10.4329/wjr.v7.i12.521.

AIM: To evaluate the feasibility of using therapeutic ultrasound as an alternative treatment option for organ-confined prostate cancer.METHODS: In this study, a trans-urethral therapeutic ultrasound applicator in combination with 3T magnetic resonance imaging (MRI) guidance was used for real-time...

Cite
Sammet S, Partanen A, Yousuf A, et al. Cavernosal nerve functionality evaluation after magnetic resonance imaging-guided transurethral ultrasound treatment of the prostate. World J Radiol. 2015;7(12):521-30doi: 10.4329/wjr.v7.i12.521.
Sammet, S., Partanen, A., Yousuf, A., Sammet, C. L., Ward, E. V., Wardrip, C., Niekrasz, M., Antic, T., Razmaria, A., Farahani, K., Sokka, S., Karczmar, G., & Oto, A. (2015). Cavernosal nerve functionality evaluation after magnetic resonance imaging-guided transurethral ultrasound treatment of the prostate. World journal of radiology, 7(12), 521-30. https://doi.org/10.4329/wjr.v7.i12.521
Sammet, Steffen, et al. "Cavernosal nerve functionality evaluation after magnetic resonance imaging-guided transurethral ultrasound treatment of the prostate." World journal of radiology vol. 7,12 (2015): 521-30. doi: https://doi.org/10.4329/wjr.v7.i12.521
Sammet S, Partanen A, Yousuf A, Sammet CL, Ward EV, Wardrip C, Niekrasz M, Antic T, Razmaria A, Farahani K, Sokka S, Karczmar G, Oto A. Cavernosal nerve functionality evaluation after magnetic resonance imaging-guided transurethral ultrasound treatment of the prostate. World J Radiol. 2015 Dec 28;7(12):521-30. doi: 10.4329/wjr.v7.i12.521. PMID: 26753067; PMCID: PMC4697126.
Copy Download .nbib Format: NLM
Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma.

Journal of contemporary brachytherapy

Donnelly ED, Rakhra S, Helenowski I, Gopalkrishnan M, Lurain J, Schink J, Singh D, Strauss J, Small W.
PMID: 23346142
J Contemp Brachytherapy. 2012 Sep;4(3):135-40. doi: 10.5114/jcb.2012.30679. Epub 2012 Sep 29.

PURPOSE: The optimal dosimetric parameters and planning techniques for high-dose-rate vaginal brachytherapy (HDR-VB) are unclear. Our aim was to evaluate the utility of bladder and rectal dosimetry for patients receiving HDR-VB for postoperative treatment of endometrial carcinoma.MATERIAL AND METHODS:...

Cite
Donnelly ED, Rakhra S, Helenowski I, et al. Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma. J Contemp Brachytherapy. 2012;4(3):135-40doi: 10.5114/jcb.2012.30679.
Donnelly, E. D., Rakhra, S., Helenowski, I., Gopalkrishnan, M., Lurain, J., Schink, J., Singh, D., Strauss, J., & Small, W. (2012). Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma. Journal of contemporary brachytherapy, 4(3), 135-40. https://doi.org/10.5114/jcb.2012.30679
Donnelly, Eric D, et al. "Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma." Journal of contemporary brachytherapy vol. 4,3 (2012): 135-40. doi: https://doi.org/10.5114/jcb.2012.30679
Donnelly ED, Rakhra S, Helenowski I, Gopalkrishnan M, Lurain J, Schink J, Singh D, Strauss J, Small W. Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma. J Contemp Brachytherapy. 2012 Sep;4(3):135-40. doi: 10.5114/jcb.2012.30679. Epub 2012 Sep 29. PMID: 23346142; PMCID: PMC3551376.
Copy Download .nbib Format: NLM
Animal models to study the mutational landscape for oral cavity and oropharyngeal cancers.

Journal of oral & maxillofacial research

Spiotto MT, Pytynia M, Liu GF, Ranck MC, Widau R.
PMID: 24422024
J Oral Maxillofac Res. 2013 Apr 01;4(1):e1. doi: 10.5037/jomr.2013.4101.

OBJECTIVES: Cancer is likely caused by alterations in gene structure or expression. Recently, next generation sequencing has documented mutations in 106 head and neck squamous cell cancer genomes, suggesting several new candidate genes. However, it remains difficult to determine...

Cite
Spiotto MT, Pytynia M, Liu GF, et al. Animal models to study the mutational landscape for oral cavity and oropharyngeal cancers. J Oral Maxillofac Res. 2013;4(1):e1doi: 10.5037/jomr.2013.4101.
Spiotto, M. T., Pytynia, M., Liu, G. F., Ranck, M. C., & Widau, R. (2013). Animal models to study the mutational landscape for oral cavity and oropharyngeal cancers. Journal of oral & maxillofacial research, 4(1), e1. https://doi.org/10.5037/jomr.2013.4101
Spiotto, Michael T, et al. "Animal models to study the mutational landscape for oral cavity and oropharyngeal cancers." Journal of oral & maxillofacial research vol. 4,1 (2013): e1. doi: https://doi.org/10.5037/jomr.2013.4101
Spiotto MT, Pytynia M, Liu GF, Ranck MC, Widau R. Animal models to study the mutational landscape for oral cavity and oropharyngeal cancers. J Oral Maxillofac Res. 2013 Apr 01;4(1):e1. doi: 10.5037/jomr.2013.4101. PMID: 24422024; PMCID: PMC3886108.
Copy Download .nbib Format: NLM
4D flow imaging with MRI.

Cardiovascular diagnosis and therapy

Stankovic Z, Allen BD, Garcia J, Jarvis KB, Markl M.
PMID: 24834414
Cardiovasc Diagn Ther. 2014 Apr;4(2):173-92. doi: 10.3978/j.issn.2223-3652.2014.01.02.

Magnetic resonance imaging (MRI) has become an important tool for the clinical evaluation of patients with cardiovascular disease. Since its introduction in the late 1980s, 2-dimensional phase contrast MRI (2D PC-MRI) has become a routine part of standard-of-care cardiac...

Cite
Stankovic Z, Allen BD, Garcia J, et al. 4D flow imaging with MRI. Cardiovasc Diagn Ther. 2014;4(2):173-92doi: 10.3978/j.issn.2223-3652.2014.01.02.
Stankovic, Z., Allen, B. D., Garcia, J., Jarvis, K. B., & Markl, M. (2014). 4D flow imaging with MRI. Cardiovascular diagnosis and therapy, 4(2), 173-92. https://doi.org/10.3978/j.issn.2223-3652.2014.01.02
Stankovic, Zoran, et al. "4D flow imaging with MRI." Cardiovascular diagnosis and therapy vol. 4,2 (2014): 173-92. doi: https://doi.org/10.3978/j.issn.2223-3652.2014.01.02
Stankovic Z, Allen BD, Garcia J, Jarvis KB, Markl M. 4D flow imaging with MRI. Cardiovasc Diagn Ther. 2014 Apr;4(2):173-92. doi: 10.3978/j.issn.2223-3652.2014.01.02. PMID: 24834414; PMCID: PMC3996243.
Copy Download .nbib Format: NLM
Passive targeting of nanoparticles to cancer: A comprehensive review of the literature.

Molecular and clinical oncology

Bazak R, Houri M, Achy SE, Hussein W, Refaat T.
PMID: 25279172
Mol Clin Oncol. 2014 Nov;2(6):904-908. doi: 10.3892/mco.2014.356. Epub 2014 Jul 23.

Cancer remains the one of the most common causes of mortality in humans; thus, cancer treatment is currently a major focus of investigation. Researchers worldwide have been searching for the optimal treatment (the 'magic bullet') that will selectively target...

Cite
Bazak R, Houri M, Achy SE, et al. Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. Mol Clin Oncol. 2014;2(6):904-908doi: 10.3892/mco.2014.356.
Bazak, R., Houri, M., Achy, S. E., Hussein, W., & Refaat, T. (2014). Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. Molecular and clinical oncology, 2(6), 904-908. https://doi.org/10.3892/mco.2014.356
Bazak, Remon, et al. "Passive targeting of nanoparticles to cancer: A comprehensive review of the literature." Molecular and clinical oncology vol. 2,6 (2014): 904-908. doi: https://doi.org/10.3892/mco.2014.356
Bazak R, Houri M, Achy SE, Hussein W, Refaat T. Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. Mol Clin Oncol. 2014 Nov;2(6):904-908. doi: 10.3892/mco.2014.356. Epub 2014 Jul 23. PMID: 25279172; PMCID: PMC4179822.
Copy Download .nbib Format: NLM
The Predictive Value of Pretreatment .

Journal of nuclear medicine & radiation therapy

Zaghloul HA, Khedr GA, Rostom Y, Refaat T.
PMID: 26779385
J Nucl Med Radiat Ther. 2014 May;5(1). doi: 10.4172/2155-9619.1000166. Epub 2014 Feb 09.

AIMS: This study aimed to evaluate the role of pretreatment 18F-Fluorodeoxyglucose positron emission tomography (MATERIALS AND METHODS: This is a retrospective study approved by the institutional review board and included LANC patients treated definitively and consecutively between January 2008...

Cite
Zaghloul HA, Khedr GA, Rostom Y, et al. The Predictive Value of Pretreatment . J Nucl Med Radiat Ther. 2014;5(1)doi: 10.4172/2155-9619.1000166.
Zaghloul, H. A., Khedr, G. A., Rostom, Y., & Refaat, T. (2014). The Predictive Value of Pretreatment . Journal of nuclear medicine & radiation therapy, 5(1), . https://doi.org/10.4172/2155-9619.1000166
Zaghloul, Hala A, et al. "The Predictive Value of Pretreatment ." Journal of nuclear medicine & radiation therapy vol. 5,1 (2014). doi: https://doi.org/10.4172/2155-9619.1000166
Zaghloul HA, Khedr GA, Rostom Y, Refaat T. The Predictive Value of Pretreatment . J Nucl Med Radiat Ther. 2014 May;5(1). doi: 10.4172/2155-9619.1000166. Epub 2014 Feb 09. PMID: 26779385; PMCID: PMC4714838.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries